We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Image: Bigstock
Time to Buy PRIMECAP Odyssey Growth Fund (POGRX)
PRIMECAP Odyssey Growth Fund (POGRX - Free Report) seeks capital appreciation. POGRX normally invests in common stocks of U.S. companies that possess high earnings growth. POGRX may invest in companies from different sectors and diverse market-cap.
This Large Cap Growth producthas a history of positive total returns for over 10 years. Specifically, the fund’s returns over the 3, 5 year benchmarks; 3 year 13.8% and 5 year almost 18.7%. To see how this fund performed compared in its category, and other #1 and #2 Ranked Mutual Funds, please click here.
POGRX’s performance, as of the last filing, when compared to funds in its category was in the top 5% over the past 1 year, and in the top 3% over the past 3 years and in the top 1% over the past 5 years.
The PRIMECAP Odyssey Growth Fund, as of the last filing, allocates their fund in top two major groups; Large Growth and Large Value. Further, as of the last filing, Abiomed Inc, Seattle Genetics Inc and Eli Lilly and Co were the top holdings for POGRX.
This Zacks Rank #2 (Buy) was incepted in November 2004 and is managed by Primecap Oddys. POGRX carries an expense ratio of 0.66% and requires a minimal initial investment of $2,000.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>